Latest Breaking News On - Navidea biopharmaceuticals - Page 14 : comparemela.com

Navidea Biopharmaceuticals, Inc (NYSE:NAVB) Sees Large Decrease in Short Interest

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily trading volume, of 5,430,000 shares, the short-interest ratio […]

Navidea biopharmaceuticals company profileNavidea biopharmaceuticals incRenaissance technologiesExchange commissionTherapeutic development programsNavidea biopharmaceuticalsFree reportDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals dailyNyse navb

Navidea Biopharmaceuticals, Inc (NYSE:NAVB) Short Interest Down 35 3% in June

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily volume of 5,430,000 shares, the […]

Renaissance technologiesNavidea biopharmaceuticals incNavidea biopharmaceuticals company profileTherapeutic development programsNavidea biopharmaceuticalsFree reportDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals daily

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Coverage Initiated at StockNews com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSEAMERICAN:NAVB opened at $0.09 on Tuesday. The business’s 50 day simple moving average is $0.13 and its […]

Navidea biopharmaceuticals incRenaissance technologiesTherapeutic development programsExchange commissionNavidea biopharmaceuticalsFree reportDiagnostic substancesTherapeutic developmentNavidea biopharmaceuticals dailyNyseamerican navbInitiated coverageStocknews com

Navidea Biopharmaceuticals rejects ProPhase Labs offer

Navidea Biopharmaceuticals Inc. announced Friday that it had rejected an unsolicited ProPhase Labs Inc. offer for certain Navidea assets, saying the proposal.

Josh wilsonNavidea biopharmaceuticals incProphase labs incNavidea biopharmaceuticalsProphase labsArticle normalNavidea biopharmaceuticals incProphase labs inc

Navidea Biopharma (NAVB) Rejects Unsolicited Offer To Acquire Certain Assets by ProPhase Labs (PRPH)

Navidea Biopharma (NAVB) Rejects Unsolicited Offer To Acquire Certain Assets by ProPhase Labs (PRPH)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNavidea biopharmaceuticals incCompany board of directorsNavidea biopharmaceuticalsExecutive consultantsProphase labs